Replies to post #154150 on Biotech Values

[JJM760]

Roy, am I sensing that you are actually turning a little bullish on Ariad??????

[iandy]

I agree with Peter. The label will dissuade some oncologists from prescribing the drug second line.
I agree with you that the unrestricted label is more important commercially.
Correct me if I am wrong but, I thought a lot of people thought the drug would have more restrictions.

[Carolepaint]

I agree.
I mean,.. I take an RA med with more troubling potential side affects! I currently, and willingly take an NSAID, with the following potential side effects!
Nonsteroidal anti-inflammatory drugs (NSAIDs) – Edema (swelling of the feet) heartburn, stomach upset and stomach ulcers and possibly increased risk of blood clots, heart attack and stroke.
And Millions of other RA patients do as well!

on a financial note:
I'm ok with this pps dive, but only because I got out early, and jumped back into the bottom, and I only hold 3,000 shares

[Carolepaint]

To DewDiligence, I also think the additional uses will give this a broader market than previously expected. I'm sure that this broader market will be a big plus for this company!
I see this a great FDA approval, even with the additional labeling.